obinutuzumab plus ibrutinib and venetoclax treatment continues to yield high response rates in cll

Published 3 years ago • 97 plays • Length 1:36

Download video MP4
Download video MP3

Similar videos

2:00

obinutuzumab, ibrutinib, and venetoclax in high-risk cll: the cll2-give and cll13 trials
4:31

sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
6:34

3-year follow-up of obinutuzumab, ibrutinib and venetoclax for cll
1:56

ibrutinib plus venetoclax for first-line treatment of cll: 4-year follow-up data
1:52

evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
5:59

6-year results of cll14: venetoclax-obinutuzumab for previously untreated cll
4:44

7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
10:24

fixed-duration therapy with venetoclax-obinutuzumab in frontline cll
2:43

four-year follow-up from a phase ii study of obinutuzumab, ibrutinib, and venetoclax in cll
2:58

results of a phase ib study of ibrutinib obinutuzumab in r/r cll
1:13

5-year follow-up of patients with cll treated in first-line with ibrutinib plus venetoclax
3:36

obinutuzumab plus venetoclax in early r/r dlbcl
1:36

cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll
1:38

improved mrd response rates in cll with obinutuzumab after ibrutinib exposure
3:22

combining venetoclax and obinutuzumab in the treatment of cll
1:17

exploratory analysis of the clarity study: ibrutinib plus venetoclax in patients with r/r cll
1:05

final analysis of the alpine trial: zanubrutinib vs ibrutinib in r/r cll
2:18

first-line ibrutinib and venetoclax in cll
1:34

the mutational profile in patients with cll treated with acalabrutinib or ibrutinib
4:38

venice i: venetoclax in r/r cll patients
1:35

cll: venetoclax in combination with obinutuzumab
5:34

venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment

Clip.africa.com - Privacy-policy